ESTEVE signs a licensing agreement for a severe primary insulin-like growth factor 1 deficiency treatment
Published on 08/07/2025 at 18:05 | prnewswire.co.uk
It is a biologic product used to treat children and adolescents from 2 to 18 years-old who suffer from severe primary insulin-like growth factor 1 deficiency1 The acquisition of the treatment for this rare disease is an example of ESTEVE's commitment focused on growth opportunities in high unmet medical and patient needs. View original content:https://www.prnewswire.co.uk/news-releases/esteve-signs-a-licensing-agreement-for-a-severe-primary-insulin-like-growth-factor-1-deficiency-treatment-302416873.html
en | boerse | 67967652 |
